The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-31 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Microcrystallization (or microcrystal test) is a method for identifying lichen metabolites that was predominantly used before the advent of more advanced techniques such as thin-layer chromatography and high-performance liquid chromatography. Developed primarily by Yasuhiko Asahina, this approach relies on the formation of distinctive crystals from lichen extracts. Although now superseded by modern analytical methods, microcrystallization still holds importance for compound purification and analysis using X-ray crystallography.
=== The IGF system === IGF1 is part of the insulin-like growth factor (IGF) system. This system consists of three ligands (insulin, IGF1 and IGF-2), two tyrosine kinase receptors (insulin receptor and IGF1R receptor) and six ligand binding proteins (IGFBP 1–6). Together they play an essential role in proliferation, survival, regulation of cell growth and affect almost every organ system in the body. Similarly to IGF1, IGF2 is mainly produced in the liver and after it is released into circulation, it stimulates growth and cell proliferation. IGF2 is thought to be a fetal growth factor, as it is essential for a normal embryonic development and is highly expressed in embryonic and neonatal tissues.
After oral administration, bupropion is rapidly and completely absorbed, reaching the peak blood plasma concentration after 1.5 hours (tmax). Sustained-release (SR) and extended-release (XL) formulations have been designed to slow down absorption, resulting in tmax of 3 hours and 5 hours, respectively. Absolute bioavailability of bupropion is unknown but is presumed to be low, at 5–20%, due to the first-pass metabolism. As for the relative bioavailability of the formulations, the XL formulation has lower bioavailability (68%) compared to the SR formulation and immediate release bupropion. Bupropion is metabolized in the body by a variety of pathways. The oxidative pathways are by cytochrome P450 isoenzymes CYP2B6 leading to R,R- and S,S-hydroxybupropion and, to a lesser degree, CYP2C19 leading to 4'-hydroxybupropion. The reductive pathways are by 11β-hydroxysteroid dehydrogenase type 1 in the liver and AKR7A2/AKR7A3 in the intestine leading to threo-hydrobupropion and by yet unknown enzyme leading to erythro-hydrobupropion. The metabolism of bupropion is highly variable: the effective doses of bupropion received by persons who ingest the same amount of the drug may differ by as much as 5.5 times (with a half-life of 12–30 hours), while the effective doses of hydroxybupropion may differ by as much as 7.5 times (with a half-life of 15–25 hours). Based on this, some researchers have advocated monitoring of the blood level of bupropion and hydroxybupropion.
Sources: en.wikipedia.org
== Institutions with hypobaric chambers == terraXcube, Eurac Research, accredited laboratory for environmental testing with large climatic chambers and medical clinic Centro de Medicina Aeroespacial de la Fuerza Aerea Colombiana, Aviation medicine, physiological, and hypobaric services Royal New Zealand Air Force Aviation Medicine Unit , Aviation medicine training and hypobaric services U.S. Army Institute of Environmental Medicine, Natick, MA, 33 years experience with its Hypobaric Chamber Facility Sheppard Air Force Base in Wichita Falls, Texas University of North Dakota's John D. Odegard School of Aerospace Sciences, Aviation Training Naval Operational Medicine Institute, Operational medical and survival training and consultative services to military forces worldwide Arizona State University Polytechnic Campus, Aircrew training, research, and other uses National AeroSpace Training And Research (NASTAR) Center South, Air and space training, research, and education RAF Centre of Aviation Medicine Center for Man in Aviation, Royal Netherlands Air Force, Aircrew training, physiology, research and certification of equipment University Hospitals Cleveland Medical Center in Cleveland, Ohio, aerospace physiology research AXA Training Center, Training ground of Liverpool F.C.
=== Range === DASH7 provides a link budget of up to 140 dB with 27 dBm transmission power, which positions the technology as medium-range, compared to short-range (Bluetooth, Wi-Fi, ...) and long-range (LoRaWAN, SigFox). Note that higher ranges are always obtained at the expense of per-bit power consumption and transmission duration. Low-power long-range technologies are generally not truly bi-directional, as the regular scanning duty is pretty high. In this context, DASH7 is a very good compromise between range, power consumption, and bi-directionality and is very suitable for industrial applications with effective range of 100 to 500 m. In line-of-sight situations, DASH7 devices today advertise read ranges of 1 kilometer or more, however, ranges of up to 10 km have been tested by Savi Technology and are easily achievable in the European Union, where governmental regulations are less constrained than in the USA.
== Reviews == Jay Rayner reviewed the restaurant for The Observer after Hibiscus moved from Ludlow to London, his first time at the restaurant. While stating that elements of the meal were "very clever indeed", such as foie gras ice cream and a sausage roll he described as a "colossus", he described the desserts as a "disappointment", calling an olive oil parfait a "gloopy mess". Overall, he planned on returning to give Bosi another chance. Zoe Williams also reviewed the restaurant shortly after it arrived in London, for The Daily Telegraph. She enjoyed her visit, and was impressed with the unusual combinations of foods that worked together saying "the sheer expertise of taking a food with a range of flavours, and knowing it's in peak condition to meet four others ... it really is something". John Walsh also visited it, for The Independent, after the restaurant arrived in London, and gave the food four stars, and the ambience and service three stars; Terry Durack reviewed it for the same paper, giving the restaurant 17 out of 20. Food critics from Time Out visited the restaurant in 2009, and were "disappointed" compared to their previous visit. They thought that Bosi's food combinations just did not work, but still said that some of his desserts were "faultless". Andy Hayler gave the restaurant a score of six out of ten on his scale during his November 2011 visit.
Stable isotope labeling involves the use of non-radioactive isotopes that can act as tracers used to model several chemical and biochemical systems. The chosen isotope can act as a label on that compound that can be identified through nuclear magnetic resonance (NMR) and mass spectrometry (MS). Some of the most common stable isotopes are 2H, 13C, 15N, and 18O, which can further be produced into NMR solvents, amino acids, nucleic acids, lipids, common metabolites and cell growth media. The compounds produced using stable isotopes are either specified by the percentage of labeled isotopes (that is, 30% uniformly labeled 13C glucose contains a mixture that is 30% labeled with 13C isotope and 70% naturally labeled carbon) or by the specifically labeled carbon positions on the compound (that is, 1-13C glucose which is labeled at the first carbon position of glucose). A network of reactions adopted from the glycolysis pathway and the pentose phosphate pathway is shown in which the labeled carbon isotope rearranges to different carbon positions throughout the network of reactions. The network starts with fructose 6-phosphate (F6P), which has six carbon atoms with a label 13C at carbon positions 1 and 2. 1,2-13C F6P becomes two glyceraldehyde 3-phosphate (G3P), one 2,3-13C T3P and one unlabeled T3P. The 2,3-13C T3P can now be reacted with sedoheptulose 7-phosphate (S7P) to form an unlabeled erythrose 4-phosphate(E4P) and a 5,6-13C F6P. The unlabeled T3P will react with the S7P to synthesize unlabeled products.
Sources: en.wikipedia.org
=== Contacts with scientists abroad === Between the 1950s and the 1970s, Hodgkin established and maintained lasting contacts with scientists in her field abroad—at the Institute of Crystallography in Moscow; in India; and with the Chinese group working in Beijing and Shanghai on the structure of insulin. Her first visit to China was in 1959. Over the next quarter century, she travelled there seven more times, the last visit a year before her death. Particularly memorable was the visit in 1971 after the Chinese group themselves independently solved the structure of insulin, later than Hodgkin's team but to a higher resolution. During the subsequent three years, 1972–1975, when she was President of the International Union of Crystallography she was unable to persuade the Chinese authorities, however, to permit the country's scientists to become members of the Union and attend its meetings. Her relations with a supposed scientist in another "People's Democracy" had less happy results. At the age of 73, Hodgkin wrote a foreword to the English edition of Stereospecific Polymerization of Isoprene, published by Robert Maxwell as the work of Elena Ceaușescu, wife of Romania's communist dictator. Hodgkin wrote of the author's "outstanding achievements" and "impressive" career. Following the overthrow of Ceausescu during the Romanian Revolution of 1989, it was revealed that Elena Ceausescu had neither finished secondary school nor attended university.
In the coming weeks, primarily using the 5-Ton cargo trucks of these NG truck companies, the 1st Brigade moved north to "tap line road" in the vicinity of Rafha, Saudi Arabia. Eventually, these National Guard truck units effectively "motorized" the 325th Infantry, providing the troop ground transportation required for them to keep pace with the French Division Daguet during the invasion. Extensive ground operations began almost six weeks later. The 2–325th INF was the division's spearhead for the ground war who took positions over the Iraqi border 24 hours in advance of U.S.-led forces at 8:00 am, 22 February 1991, on Objectives Tin Man and Rochambeau. On 23 February, 82nd Airborne Division paratroopers protected the XVIII Airborne Corps flank as fast-moving armor and mechanized units moved deep inside south-western Iraq. After the second day, the 1st Brigade moved forward to extend the Corps flank along with 3d Brigade. The 82nd drove deep into Iraq and captured thousands of Iraqi soldiers and tons of equipment, weapons, and ammunition. During that time, the 82nd's band and MP company processed 2,721 prisoners. After the liberation of Kuwait and the surrender of the Iraqi Army, the 82nd redeployed to Fort Bragg.
MRI requires a magnetic field that is both strong and uniform to a few parts per million across the scan volume. The field strength of the magnet is measured in teslas – and while the majority of systems operate at 1.5 T, commercial systems are available between 0.2 and 7 T. 3T MRI systems, also called 3 Tesla MRIs, have stronger magnets than 1.5 systems and are considered better for images of organs and soft tissue. Whole-body MRI systems for research applications operate in e.g. 9.4T, 10.5T, 11.7T. Even higher field whole-body MRI systems e.g. 14 T and beyond are in conceptual proposal or in engineering design. Most clinical magnets are superconducting magnets, which require liquid helium to keep them at low temperatures. Lower field strengths can be achieved with permanent magnets, which are often used in "open" MRI scanners for claustrophobic patients. Lower field strengths are also used in a portable MRI scanner approved by the FDA in 2020. Recently, MRI has been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla range, where sufficient signal quality is made possible by prepolarization (on the order of 10–100 mT) and by measuring the Larmor precession fields at about 100 microtesla with highly sensitive superconducting quantum interference devices (SQUIDs).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.